New pill aims to tackle obesity and inflammation at the same time

NCT ID NCT07693868

Not yet recruiting Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug, NNC6022-0004, in healthy adults and people with obesity. The study checks how safe the drug is, how the body processes it, and whether food affects its absorption. Participants receive either the drug or a placebo capsule by chance. The goal is to gather initial safety data before larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC6022-0004 (oral capsule)
What this could lead to: If safe and effective, this drug could offer a new oral treatment option for obesity and related inflammation.
What could go wrong: This is an early Phase 1 trial focused on safety, not efficacy. The drug may not work or could have side effects. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ELEVATED HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ELEVATED HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP) OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ICON - location Groningen

Groningen, 9728 NZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.